share_log

Candel Therapeutics (NASDAQ:CADL) Trading Down 5.3%

Defense World ·  Sep 22, 2022 02:01

Shares of Candel Therapeutics, Inc. (NASDAQ:CADL – Get Rating) fell 5.3% during mid-day trading on Wednesday . The company traded as low as $3.20 and last traded at $3.21. 6,148 shares were traded during trading, a decline of 82% from the average session volume of 33,482 shares. The stock had previously closed at $3.39.

Wall Street Analyst Weigh In

Separately, Credit Suisse Group lowered their price objective on shares of Candel Therapeutics to $11.00 in a research report on Monday, August 15th.

Get Candel Therapeutics alerts:

Candel Therapeutics Stock Down 5.3 %

The company has a debt-to-equity ratio of 0.34, a quick ratio of 14.86 and a current ratio of 14.86. The stock has a market capitalization of $92.74 million, a P/E ratio of -3.96 and a beta of 0.95. The stock's fifty day simple moving average is $3.41 and its two-hundred day simple moving average is $3.81.

Institutional Investors Weigh In On Candel Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Empirical Asset Management LLC bought a new stake in shares of Candel Therapeutics in the 1st quarter valued at $61,000. Kestra Advisory Services LLC bought a new stake in shares of Candel Therapeutics in the 1st quarter valued at $64,000. 683 Capital Management LLC bought a new stake in shares of Candel Therapeutics in the 4th quarter valued at $320,000. BlackRock Inc. boosted its stake in shares of Candel Therapeutics by 15.5% in the 1st quarter. BlackRock Inc. now owns 132,322 shares of the company's stock valued at $674,000 after purchasing an additional 17,708 shares during the last quarter. Finally, Point72 Asset Management L.P. bought a new stake in shares of Candel Therapeutics in the 2nd quarter valued at $2,408,000. 21.97% of the stock is owned by institutional investors.

Candel Therapeutics Company Profile

(Get Rating)

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.

Featured Articles

  • Get a free copy of the StockNews.com research report on Candel Therapeutics (CADL)
  • The Worst May be Over for Target, But is the Stock Safe to Buy?
  • Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
  • Two Fun Stocks The Insiders Are Buying
  • Novavax Remains a Risk-On Stock in a Risk-Off Market
  • 3 Defensive Stocks With 60-Year Dividend Hike Streaks

Receive News & Ratings for Candel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Candel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment